the company developed "hepatitis B virus, hepatitis C virus, human immunodeficiency virus (type 1) nucleic acid detection kit (PCR-fluorescence method)" won the National Food Drug Administration on November 9, 2010 issued by the "new drug certificate" and "Drug Registration Approval Document." New Drug Certificate Number: Sinopharm card characters S20100005, Drug Approval Number: Zhunzi S20100011.

Branch, blood safety is currently the largest supplier of test kits, has been concerned blood screening development and application of new technologies, years ago, officially launched the blood screening with nucleic acid detection reagents, and was listed as "Project of Shanghai Municipal Science and Education" and "National Eleventh Five major projects." The approval of the "triple screen blood DNA kit" can more effectively reduce the detection window period, to improve virus detection rates and reduce transfusion risk.

Health Administration in accordance with this year's meeting schedule, relying on the latest development of the "triple nucleic acid blood screening reagents, "Branch, also created a fully automated nucleic acid workstation, and blood banks in some areas to carry out the pilot nucleic acid testing in blood screening. As the blood screening nucleic acid detection technology pioneer, Branch, will continue with the latest diagnostic technology and products into the market, to high-end technology services to the people's livelihood, to ensure the safety of blood for clinical use.